Committee & streams

Global Steering Committee

The IDF World Diabetes Congress 2025 Global Steering Committee is composed of international experts who are engaged to promote the congress within their country and region, as well as at national and international events, and leverage relationships with industry partners and key opinion leaders to secure participation and sponsorship at the event.

Discover the Global Steering Committee Members

Programme Committee

The programme of the IDF World Diabetes Congress 2025 is organised across ten streams.

Chair

Antonio Ceriello

Italy

Co-Chair

Iryna Vlasenko

Ukraine

National Advisory Committee Chair

Wannee Nitiyanant

Thailand

Streams

Basic and Translational
Science
(BTS)
Lead
Michael Roden

Germany

Members
Viswanathan Mohan

India

Linong Ji

China

Mary Elizabeth Patti

USA

Kohjiro Ueki

Japan

Classification and
Differential Management
of Diabetes (CDM)
Lead
Juliana Chan

China

Members
Jaakko Tuomilehto

Finland

Sarah Wild

UK

Lee-Ling Lim

Malaysia 

Technology and
Artificial Intelligence
(TAI)
Lead
Tadej Battelino

Slovenia

Members
Mauro Scharf Pinto

Brazil

Alice Cheng

Canada

Revital Nimri

Israel

Diabetes
Complications
(DC)
Lead
Andrew Boulton

United Kingdom

Members
Rayaz Malik

Qatar

Naveed Sattar

UK

Vijay Viswanathan

India

Type 1
Diabetes
(T1D)
Lead
Paolo Pozzilli

Italy

Members
David Leslie

UK

Raffaella Buzzetti

Italy

Banshi Saboo

India

Public Health
and Policy
(PHP)
Lead
Akhtar Hussain

Norway

Members
Zumin Shi

Qatar

A.K Azad Khan

Bangladesh

Fadlo Fraige Filho

Brasil

Education and
Integrated Care
(EIC)
Lead
Jacko Abodo

Côte d’Ivoire

Members
Bernard Omech

Uganda

Jackie Maalouf

Lebanon

Hinde Iraqi

Marocco

Epidemiology &
Prevention of Diabetes
(EPD)
Lead
Peter Schwarz

Germany

Members
Bishwajit Bhowmik

Bangladeshi

Pablo Aschner

Colombia

Josip Car

UK

Women and
Diabetes
(WAD)
Lead
Maria Ines Schmidt

Brazil

Members
Nayla do Vale Moreira

Norway

Usha Sriram

India

Ravi Rajan Retnakaran

Canada

Living with
Diabetes
(LWD)
Lead
Jean Claude Mbanya

Cameroon

Members
Aslam Amod

South Africa

Nupur Lalvani

India

Lurline Less

Jamaica

Programme Chair

Antonio Ceriello (Italy)

Professor Antonio Ceriello is Research Consultant at IRCCS MultiMedica, Milan, Italy and Adjunct Professor of Internal Medicine at Luigi Vanvitelli University in Naples, Italy. He has widely published in diabetes, with over 550 original papers and several book chapters. He is currently Editor in Chief of the official IDF journal, Diabetes Research and Clinical Practice.

Co-Chair

Iryna Vlasenko (Ukraine)

Dr Iryna Vlasenko is an international expert in diabetes, currently a Vice President of the International Diabetes Federation. She has contributed to developing national and international regulatory documents and medical standards. In addition, her regular participation in government and key stakeholder meetings and attendance at international congresses has raised awareness of diabetes and brought about policy change. Dr Vlasenko’s areas of research include pharmaceutical care for people with diabetes, therapeutic education for people with NCDs and healthcare reform.

Streams

Basic and Translational Science (BTS)
Michael Roden (Germany)

Michael Roden is Chair/ Professor of Endocrinology and Metabolic Disorders, Director of the Division of Endocrinology and Diabetology at Heinrich Heine University and University Hospital Düsseldorf and CEO of the German Diabetes Center (DDZ). His research focuses on energy metabolism in obesity, diabetes and steatotic liver diseases, with paradigm-changing contributions to lipid-induced insulin resistance, mitochondrial function and novel diabetes subtypes paving the way to precision diabetology. Professor Roden is a highly cited researcher (Clarivate 2022, 2023) with >750 peer-reviewed publications and co-leadership of (inter)national guidelines. He has received various awards (e.g. EASD-Minkowski Prize, Morgagni Gold Medal, Langerhans Medal), honorary doctorates (Athens, Belgrade) and served on boards of diabetes associations (EASD, chairman/EFSD, president/CEDA, ÖDG, congress president/DDG).

Dr. Patti is a physician-scientist, Senior Investigator at Joslin Diabetes Center, Director of the Hypoglycemia Clinic, and Associate Professor of Medicine at Harvard Medical School.  Her NIH-funded laboratory studies are focused on identification of molecular and epigenetic mechanisms by which environmental/nutritional factors during early life confer metabolic disease risk in later life and in subsequent generations.  Clinical/translational studies focus on the intestine as a mediator of systemic glucose metabolism and its alterations after bariatric surgery, and novel approaches to treatment of post-bariatric hypoglycemia. Dr. Patti received her MD from Jefferson Medical College magna cum laude, internal medicine residency at University of Pittsburgh and endocrinology fellowship at Harvard Medical School.  Dr. Patti has held numerous leadership roles in the diabetes community, including organizer of a diabetes-focused Keystone Symposium, chair of ADA Scientific Sessions Planning Committee, and NIH study section member.  She was elected to the American Society of Clinical Investigation, Association of American Physicians, and to Fellowship in both American College of Physicians and Obesity Society.

Prof. Kohjiro Ueki MD. PhD. graduated from medical school, the University of Tokyo in 1987. He was trained as a physician and diabetologist at the University of Tokyo Hospital, and obtained PhD degree from the University of Tokyo. In 1997, he joined Joslin Diabetes Center, Harvard Medical School as a postdoctoral fellow and became Instructor in 2001. He served as Associate Professor at Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, the University of Tokyo from 2004 through 2014, and became Professor at Department of Molecular Sciences on Diabetes in 2014. Since 2016, he has been working at Diabetes Research Center, National Center for Global Health and Medicine, as Director. He has also served as Professor at Department of Molecular Diabetology, the University of Tokyo since 2020. In the Japan Diabetes Society, he has been Cahir of the Board of Directors since 2020.

Classification and Differential Management of Diabetes (CDM)
Juliana Chan (China)

Juliana Chan is Chair Professor of Medicine and Therapeutics and Director, Hong Kong Institute of Diabetes and Obesity at The Chinese University of Hong Kong, Prince of Wales Hospital. She is a physician researcher specialised in diabetes and clinical pharmacology. Her research interests include using registers to define causes and consequences of diabetes and implement data driven integrated care and pragmatic clinical trials accompanied by biobanks to discover disease pathways to predict, prevent and classify diabetes for personalised care. Professor Chan has published 900 original articles and 20 book chapters. She has received several international awards and leads The Lancet Commission Report which advocates for the use of data to transform diabetes care.

Technology and Artificial Intelligence (TAI)
Tadej Battelino (Slovenia)

Tadej Battelino completed his medical degree at the University of Ljubljana in 1990. He completed a PhD focusing on glucose metabolism in neonatal endotoxic shock in 1996. He completed his clinical fellowship at Loyola University of Chicago, USA, and his postdoctoral fellowship at INSERM, Paris, France. Professor Battelino is currently Consultant and Head of Department of Pediatric and Adolescent Endocrinology, UMC Ljubljana, Head, Chair of Pediatrics, and Professor of Paediatrics at Faculty of Medicine, University of Ljubljana. He is PI on several publicly funded research projects in the field of diabetes, endocrinology and metabolism, and has received several awards, including the Slovene national award for research in 2014, the Gold medal for research at the University of Ljubljana in 2017, the ISPAD Achievement Award in 2020 and the Presidential Medal from Children with Diabetes society in 2022. Professor Battelino serves on the editorial boards for the journals Diabetes Care, Journal of Pediatric Endocrinology and Metabolism, Acta Diabetologica, and was Editor for the European Journal of Endocrinology from 2009 to 2015. He has authored or co-authored over 316 papers in international peer-reviewed journals and participated chapters to several international books. 

Alice Cheng is an Endocrinologist at Trillium Health Partners and Unity Health Toronto and an Associate Professor at the University of Toronto.  She has been involved with the development of the Diabetes Canada clinical practice guidelines since 2003 and served as Chair for the 2013 version.  She is currently  serving as Chair of the Scientific Planning Committee for the 2024 American Diabetes Association annual scientific meeting. In recognition of her contribution to the diabetes community, she has received the national Charles H. Best Award and the Gerald S. Wong Service Award from Diabetes Canada.

Revital Nimri is a senior endocrinologist, the Director of the Scientific and Technology Diabetes Unite, and the Diabetes Technology Center at the Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children’s Medical Center of Israel, and Professor of Pediatrics, Faculty of Medical and Health Science, Tel-Aviv University. She has a 20-year track record of expertise in clinical diabetes, and over the last decade has focused solely on new and innovative technologies for treating diabetes. Her research interests include basic and clinical research with a special emphasis on technology.

Diabetes Complications (DC)
Andrew Boulton (UK)

Professor Andrew Boulton is the Immediate Past President of the International Diabetes Federation (IDF). He is currently President of the Worldwide Initiative for Diabetes Education and Chair of the European Alliance for Diabetes Research (EURADIA). Professor Boulton is a graduate of Newcastle-upon-Tyne University. He subsequently trained in Sheffield and Miami prior to accepting an appointment at Manchester University, where he is currently Professor of Medicine with a special interest in diabetes and its complications. He is also Consultant Physician at Manchester Royal Infirmary.

Rayaz Malik graduated in Medicine from the University of Aberdeen in 1991, obtained his MRCP in 1996, PhD from the University of Manchester in 1997 and FRCP in 2007. He was Professor of Medicine and Consultant Physician in Central Manchester University Teaching Hospitals and the University of Manchester (2008-2014). He was appointed as Professor of Medicine at Weill Cornell Medicine-Qatar and Senior Physician in Endocrinology and Internal Medicine at Hamad General Hospital in 2014. His research focuses on the pathogenesis, assessment and treatment of diabetic neuropathy and neurodegenerative diseases like Stroke, Multiple Sclerosis, Parkinson’s disease, and Dementia.

Professor Naveed Sattar is an Honorary Consultant at the Glasgow Royal Infirmary, co-leading a CVD prevention clinic. He graduated from the University of Glasgow in 1990. In 1993 he moved to Glasgow Royal Infirmary, first as a Specialist Registrar, then as Senior Lecturer and Reader. He was awarded a PhD from the University of Glasgow in 1998. After that, he joined the staff of the University of Glasgow and, in early 2005, was appointed as Professor of Metabolic Medicine at the Institute of Cardiovascular & Medical Sciences. Prof. Sattar is a Fellow of the Royal College of Pathologists, the Royal College of Physicians and Surgeons, Glasgow, the Royal Society of Edinburgh and the UK Academy of Medical Sciences.

Vijay Viswanathan is a Practising Diabetologist in Chennai India and has completed 31 years in this field. He has a special interest in diabetes foot care, diabetes and the kidney and diabetes in people with TB infection. He is the chief diabetologist of a tertiary care centre exclusively for diabetes care in India established in 1954.

Type 1 Diabetes (T1D)
Paolo Pozzilli (Italy)

Paolo Pozzilli is Professor of Endocrinology at Campus Bio-Medico University of Rome, Italy, and Professor of Diabetes and Clinical Research at the Centre of Immunobiology, Blizard Institute, St Bartholomew’s and the London School of Medicine, Queen Mary University of London, UK. He works in the field of diabetes with particular focus on type 1 diabetes pathogenesis and prevention. He has published over 560 scientific articles (PubMed), books and reviews on different aspects of diabetes, from basic studies on the autoimmune mechanisms of T1D to late complications of the disease. He is actively engaged in clinical trials testing novel therapies for type 1 and type 2 diabetes. He is Editor in Chief of Diabetes Metabolism Research and Reviews, and Coordinator of the Master’s Degree Programme in Medicine and Surgery at Campus Bio-Medico University of Rome. Professor Pozzilli has received several awards, including the Andrew Cudworth Memorial Award by the British Diabetic Association (1984), the Morgagni Award for Best Young Investigator by the International Society of Metabolism (1989), the Marie Kugel Award by the Juvenile Diabetes Foundation USA (2003 and 2007), and the Diabetes Honoris Causa Award by the Paulescu Foundation, Romanian Diabetes Society (2013).

Richard David Leslie is Professor of Diabetes and Autoimmunity at St Bartholomew’s Hospital and the Blizard Institute, University of London. Elected President of the Association of Physicians of Great Britain in 2012, he was awarded a Wellcome Trust Senior Fellowship in Clinical Science, an MRC Travelling Fellow in USA, and is Emeritus Professor in Central South University, China. As Principle Investigator of three major European Union programmes (BLUEPRINT, Action LADA and EXALT), he is a world leader in several areas of diabetes research.

Dr Banshi Saboo is Chief Diabetologist and Chairman of the Diabetes Care & Hormone Clinic, Ahmedabad, India. He is also the Chair-Elect for the IDF South-East Asia (SEA) Region, Honorary Secretary of Diabetes India, an Honorary Vice President of the Diabetes in Asia Study Group (DASG) and previously served as President of the Indian Obesity Society (AIAARO) and the Research Society for Study of Diabetes in India (RSSDI). Dr Saboo has been responsible for several diabetes education and awareness projects in India and has authored more than 50 publications in indexed journals.

Public Health and Policy (PHP)
Akthar Hussain
Akhtar Hussain (Norway)

Professor Akhtar Hussain is President of the International Diabetes Federation (2022-24). He previously served on the IDF Board as a Vice President (2013-2017) and President-Elect (2020-21). Prof. Hussain is originally from Bangladesh. After graduating in medicine from the University of Dhaka, Bangladesh, he received post-graduate and doctoral diplomas in Boston, USA and Bergen and Oslo, Norway, where he has resided since 1982. Over the last 25 years, Prof. Hussain has worked actively in diabetes and is currently a professor at NORD University in Norway, focusing on diabetes and metabolic syndrome.

Education and Integrated Care (EIC)
Jacko Abodo (Côte d'Ivoire)

Professor Jacko Obodo is Chair of the IDF Africa Region. He is is Head of the Department of Endocrinology and Diabetology and Deputy Head of the Medical Commission Yopougon Teaching Hospital in Abidjan, Côte D’Ivoire. Much of his work focuses on diabetes, obesity and diabetes-related NCDs. As such, he is an expert in the WHO Global NCD Platform. In addition, his advocacy work includes leading diabetes and NCD associations and serving on the boards of regional associations.

Bernard Omech, MD, MPH, is a consultant Physician and Chair for Internal Medicine at Lira University Teaching Hospital, Lira City, Uganda. He is also a Senior Lecturer and Acting Director of graduate Training and Research of Lira University and a clinical Researcher Diabetes and  affiliate member of the East African Diabetes Study Group.

Jackie Kassouf Maalouf holds a Ph.D. in Public Relations & Communications from the University of Corllins in Virginia, USA. In January 2011, she founded, the National Diabetes Organization DiaLeb, together with her daughter, Sylvie, who has type 1 diabetes, and has acted as the association’s president since then. She holds a diabetes educator certificate and has accomplished several diabetes related certifications with the University of Copenhagen. She is currently a Vice President of the International Diabetes Federation.

Epidemiology and Prevention of Diabetes (EPD)
Peter Schwarz (Germany)

Professor Peter Schwarz is President-Elect of the International Diabetes Federation. He specialises in the prevention and care of diabetes and is a research group leader at the Paul Langerhans Institute Dresden (PLID), a partner site of the German Center for Diabetes Research (DZD). His research covers molecular and clinical mechanisms to treat and prevent type 2 diabetes. He is also developing and evaluating digital tools such as mobile smartphone applications targeting the common lifestyle-associated risk factors of type 2 diabetes. 

Bishwajit Bhowmik is Project Director at the Centre for Global Health Research (CGHR) of Diabetic Association of Bangladesh and General Secretary of Diabetes in Asia Study Group (DASG). He holds a diploma in diabetes medicine from the UK and a PhD. from the University of Oslo, Norway. He has authored 51 international publications, contributed four book chapters, and is a member of the editorial board of over 25 books/guidelines. 

Pablo Aschner is an Associate Professor of Endocrinology at the Javeriana University School of Medicine and Senior Research Advisor at San Ignacio University Hospital. He is also the Scientific Director of the Colombian Diabetes Association. He graduated in Medicine and Surgery from the Javeriana University, Bogotá, and undertook postgraduate training in Internal Medicine and Endocrinology at the Military Hospital, Bogotá, and at Cambridge University, UK. Prof Aschner’s main research interests include prevention of type 2 diabetes in the real world as well as diagnosis, control and treatment of diabetes and its complications, with emphasis on the development of evidence-based clinical guidelines. 

Professor Josip Car serves as the Head of King’s School of Life Course & Population Sciences and holds the Chair in Population and Digital Health Sciences. With over 500 multidisciplinary experts, the School research is global, pioneering world-changing discoveries and translating them into advances in medicine and health systems. Prior to joining King’s, he served in a range of leadership roles in Singapore and the UK including as the Founding Director of the WHO Centre for Digital Health and Health Education, and Director of Public Health, Primary and Integrated Care at Imperial College Healthcare, of NIHR Primary Care Research Network for London (NW) and of Global Digital Health Unit. 

Women and Diabetes (WAD)
Maria Ines Schmidt (Brazil)

Maria Ines Schmidt was trained as an endocrinologist at the John Hopkins Hospital and an epidemiologist at the University of North Carolina. As a professor at the School of Medicine, Federal University of Rio Grande do Sul, Brazil, her research has focused on type 2 diabetes and gestational diabetes. Her current projects include LINDA Brasil (Life Style Interventions for Diabetes Prevention After Pregnancy), a randomized controlled trial for the prevention of diabetes in women with previous gestational diabetes. Maria has participated in national and international guidelines for gestational diabetes and collaborated with the diabetes in women stream of the IDF World Diabetes Congress.

Dr Nayla Cristina do Vale Moreira is currently working as an associate professor at Nord University, Norway. She graduated in Medicine, with a specialization in Family Medicine from the Federal University of Ceará, Brazil. Subsequently she obtained a MPhil degree on type 2 diabetes and depression, as well as PhD on diabetes and cardiovascular risk from the University of Oslo, Norway. She has been working actively on diabetes research in cooperation with several international partners.

Usha Sriram is an endocrinologist who has dedicated her professional career to women’s health in general and their reproductive health in particular. Her belief that women’s life course has great impact on all aspects of their mental and physical health has been a guiding principle in her approach to women’s health issues. Dr Sriram is a strong voice for women’s health and empowerment. She is a frequent invited speaker at national and international conferences and respected as a thought leader in diabetes, gestational diabetes, women’s reproductive and hormonal issues.

Ravi Retnakaran is a Professor of Medicine at the University of Toronto and an endocrinologist and clinician-scientist at Mount Sinai Hospital in Toronto, Canada, where he holds the Boehringer Ingelheim Chair in Beta-cell Preservation, Function and Regeneration. He was awarded the 2013 Dr. Charles Hollenberg Young Investigator Award by the Canadian Society of Endocrinology and Metabolism and the 2014 Joe Doupe Award from the Canadian Society of Clinical Investigation. In 2020, he was named to the Canadian Academy of Health Sciences. His research programme focuses on the pathophysiology and treatment of type 2 diabetes, with a particular interest in the potential reversibility of pancreatic beta-cell dysfunction early in the course of diabetes. 

Living with Diabetes (LWD)
Jean Claude Mbanya (Cameroon)

Jean Claude Mbanya is Professor of Medicine and Endocrinology at the Faculty of Medicine and Biomedical Sciences, Director of Biotechnology Centre and Postgraduate Dean Doctoral School of Life, Health and Environmental Sciences, University of Yaoundé 1, Yaoundé, Cameroon. Professor Mbanya initially studied in Cameroon where he obtained his MD before continuing his training at the University of Newcastle upon Tyne, England, where he obtained a PhD and eventually MRCP (UK). He is Fellow of the Royal College of Physicians, London, Fellow of the World Academy of Sciences, Trieste, Italy, and received a Doctor philosophiae honoris causa from the University of Oslo in 2011 for his outstanding international leadership in the field of diabetes. He is also the recipient of the American Diabetes Association 2004 Harold Rifkin award for Distinguished International Service in the Cause of Diabetes. Professor Mbanya is currently Honorary President of the International Diabetes Federation (IDF) after serving as President from 2009-2012. He has authored several books and book chapters and published over 240 papers in peer-reviewed journals.

Dr. Lurline Less is a wife, mother, healthcare consultant, Diabetes Care & Education Specialist and entrepreneur. She has 24 years of experience in the health care field and worked with the Ministry of Health and Wellness and PAHO on strategic planning and diabetes education programmes. She is the past Chairman of the Diabetes Association of Jamaica and the past chairman of the North America and Caribbean Region (NAC) of the International Diabetes Federation (IDF). Her work has been dedicated to improving diabetes care through self-management education as well as managing efficient health delivery systems.  

Stream descriptions and learning objectives

The Basic and Translational Science stream addresses recent progress in diabetes research ranging from experimental models to mechanistic studies in humans. The topics are selected regarding ground-breaking evidence for novel findings and regarding their relevance to future application in diabetes management.

Learning objectives
Having attending this stream´s sessions, the participants will have:

  • Cutting-edge knowledge on diabetes development and progression
  • Expertise in new methods and biomarkers of type 1 and type 2 diabetes
  • Comprehensive information on novel mechanisms leading to diabetes comorbidities
  • Insights into novel subtypes of (pre)diabetes and their role for stratified prevention and treatment of diabetes

This stream focuses on latest advancements in understanding diabetes subtypes, diagnostic criteria, and personalised treatment approaches.

Learning objectives
After attending the sessions in the Classification of diabetes and differential management of diabetes stream, the participant will be:

  • Understand the dynamic classifications of diabetes, exploring various subtypes and their implications for refined diagnosis and management.
  • Learn about the latest diagnostic criteria and tools, enabling healthcare professionals to identify different forms of diabetes with precision and accuracy.
  • Gain practical insights on applying strategies for tailoring diabetes management based on individual patient characteristics, ensuring more effective and targeted treatment plans.
  • Stay informed about cutting-edge research in diabetes classification and management, recognising the potential impact on clinical practices and patient care.
  • Acquire skills to better understand and apply refined classification methods and personalized management approaches, ultimately leading to improved patient outcomes and enhanced quality of diabetes care.
  • New possible criteria for the early diagnosis of diabetes and intermediate hyperglycemia: a Position Statement from IDF.

Technology is now positioned in the center of routine diabetes management. Artificial Intelligence uses Continuous Glucose Monitoring (CGM) data for automated insulin dosing in Advanced Hybrid Closed Loop (AHCL) systems for individuals with type 1 diabetes (T1D), and in Clinical Decision Support Systems (CDSS) for all other glucose management in different clinical situations. CGM is the preferred diabetes management tool by individuals with diabetes; however, its accessibility in different regions remains a barrier that needs focused attention. Several Apps using CGM, connected pens and/or other inputs help with daily diabetes management and stimulate necessary behavioral modifications  in individuals with intermittent hyperglycemia, obesity, and metabolic syndrome.

Learning objectives
A participant will acquire the following specific knowledge:

  • Routine clinical use of Advanced Hybrid Closed Loop (AHCL) systems in type 1 diabetes (T1D) and pregnancy complicated with T1D
  • Routine use of CGM and Connected pens in Multiple Daily Injections (MDI) therapy
  • The use of Clinical Decision Support Systems (CDSS) and Apps for routine diabetes management in different settings
  • The clinical use of CGM, Apps and additional technology in individuals with intermittent hyperglycemia and obesity for behavioral modification
  • Current information on advanced developments in diabetes technology
  • CGM use in Type 2 Diabetes not on insulin treatment

The Diabetes Complications stream will address recent progress in both clinical and both basic research in the area of not only microvascular complications of diabetes (retinopathy, nephropathy, neuropathy) but also cardiovascular disease.  It will also explore the increasing connection between “Cardio Diabetes” and “Cardio Renal Diabetes” and the use of modern medications that might be of assistance in these particular areas.

Learning objectives
After attending session in the Diabetes Complications stream, the participant will be:

  • Updated in latest research in the pathogenesis and pathophysiology of diabetes complications.
  • Will be updated in recent developments in evidence-based management of diabetic neuropathy and diabetic foot problems.
  • Will understand the impact of artificial intelligence and smart technology particularly in the area of diabetic retinopathy screening.
  • Understand that it is essential to screen for all microvascular and macrovascular complications in all patients with diabetes at least on an annual basis as these may be silent in their early stages.
  • Be updated in changes of screening and methodology during this decade.
  • Understand the impact of late complications of diabetes on people with diabetes quality of life and their impact on aspects of daily living and how it might affect other family members.

By attending this stream’s session, participants will acquire knowledge on:

  • Current status of type 1 diabetes (T1D) prevention and the different approaches undergoing for such purpose. Currently, there is no proven way to prevent T1D although promising results have been obtained.
  • Ongoing efforts to explore strategies for prevention of T1D in the early manifestations of hyperglycaemia are available. This starts from:
    *identification of subjects with biomarkers of autoimmunity to allow early intervention to prevent beta cell destruction.
    *Different immunotherapy trials are now ongoing in subjects with early signs of hyperglycaemia that modulate the immune system to prevent and delay extensive beta cell destruction.
    *The long term maintenance of C-peptide secretion is the goal of these novel forms of therapy.
  • The issue of new drugs use for CVD prevention in type 1 diabetes

This stream will focus on health systems and policies that affect diabetes care, and most importantly people living with diabetes. There will be a focus on both the wider funding of healthcare in general, and on policies that impact diabetes care at a micro and macro level. 

Learning objectives
After attending the sessions in the Public Health and Policy stream, the participant will be able to:

  • Learn about trends at a governmental level on funding mechanisms
  • Understand how policies affect diabetes care
  • Understand how the most effective health systems deal with funding and provision challenges
  • Learn about innovative policies that lead to better diabetes care
  • Hear about how people with diabetes contribute to effective policy making and influence

This stream focuses on all aspects related to diabetes education, self-management and diabetes support, with a particular focus on diabetes care delivered by healthcare providers, peers, families or communities, as well as diabetes management systems/models integrated into diabetes tools with diabetes detection, blood glucose monitoring, diet or physical activity. All this improved by diabetes technology.

Diabetes technology: historically divided into two main categories: insulin delivered by syringe, pen, patch, or pump (also called continuous subcutaneous insulin infusion [CSII]) and glucose assessed by monitoring Blood Glucose Monitoring (BGM) or continuous glucose monitoring (CGM), diabetes technology has expanded to include automated insulin delivery (AID) systems, in which CGM-based algorithms modulate the insulin administration, connected insulin pens, as well as diabetes self-management software serving as medical devices. Diabetes technology, when combined with education, monitoring and support, can improve the lives and health of people with diabetes; However, the complexity and rapid evolution of the diabetes technology landscape may also pose a barrier to implementation for people with diabetes, their care partners, and the care team.

Learning objectives

  • Teach people how to live with diabetes.
  • Optimize training course design
  • Focus on diabetes education or care with emphasis on
    *diabetes detection
    *screening for complications (microvascular, macrovascular, co-morbidities for multidisciplinary and integrated care (NCD framework in primary health care (WHO-PEN / WHOPEN-PLUS: and
  • Utilize both classic and improved tools
  • Overcome language barriers
    *develop or offer educational programs and materials in culturally adaptive languages for improving their cultural competency, addressing health literacy, and ensuring communication with language assistance

This stream deals with updates on recent research and advances on the epidemiology of diabetes diagnosis, complications and prevention, the public health challenges being faced and how to prevent and deal with them.

Learning objectives

After attending the sessions in the Epidemiology and Public Health stream, the participant will be able to:

  • Understand the importance of rigorous methodology when undertaking epidemiology studies
  • Recognise the gaps in epidemiology research that need to be filled
  • Understand how to overcome current and emerging challenges to metabolic health
  • Describe how current epidemiological data can be used to help shape future policy and healthcare implementation
  • Translate successful strategies from projects presented into future prevention and management programmes
  • How artificial intelligence can add to epidemiology and public health

This stream will focus on the best evidence to treat and prevent diabetes and related conditions among women, including hyperglycaemia in pregnancy (HIP) and its long-term effects on mother and child.  

Learning objectives
After attending the sessions in the Diabetes in Women stream, the participant will be able to:

  • Identify key issues deserving special attention in the care of women with diabetes.
  • Use current best evidence to inform health policy and clinical decision-making for issues related to diabetes in women.
  • Understand that HIP is a common condition associated with higher incidence of maternal morbidity, perinatal and neonatal morbidity, and long-term consequences for both mother and child.
  • Consider a life-course approach to the prevention of diabetes and its complications focused on the prevention and treatment of HIP. 

This stream gives an in-depth perspective of people living with diabetes.  Diabetes is about me! I am the key to successfully managing my diabetes. The stream will share real life experiences of diabetes acceptance, education and understanding, self-management, prevention of complications, support and advocacy.

Learning objectives

After attending the sessions in the Living with Diabetes stream, the participant will be able to:

  • Educate, motivate, and support people with diabetes to achieve better health outcomes
  • Overcome challenges to improve compliance in:
    • Healthy eating
    • Physical activity and sport
    • Monitoring
    • Managing complications (and preventing costly complications).
  • Recognise the lifestyle changes required and difficulties to achieve them
  • Share experiences of support systems and solutions that work
  • Use technology to assist with daily routines to achieve self-management goals
  • Identify and analyse barriers and enablers to empowerment and positive self-care
  • Understand how peer-to-peer support can be used in routine medical practice
  • Understand that different ages need different models of care

Basic and Translational Science (BTS)

Clinical, Therapeutic and
Technology Research (CTT)

Diabetes Complications and
Comorbidities (DCC)

Diabetes in Women (DIW)

Education and Integrated Care (EIC)

Epidemiology and Public Health (EPH)

Health Services and Policy (HSP)

Living with Diabetes (LWD)

This stream addresses recent progress in diabetes research and its future applications in diabetes care as well as the latest advances in science-based clinical practice.

This stream deals with current and future areas of clinical therapeutics, diabetes technology and future research direction.

This stream deals with current and future areas of clinical therapeutics, diabetes technology and future research direction.

This stream will focus on the best evidence to treat and prevent diabetes and related conditions among women, including hyperglycaemia in pregnancy (HIP) and its long-term effects on mother and child.

This stream focuses on all aspects related to diabetes education and diabetes self-management and support, with a particular interest on diabetes care delivered by healthcare providers, peers, families, or communities, as well as on diabetes management systems/models integrated with tools dealing with diabetes detection, glucose monitoring, diet, or physical activity.

This stream deals with updates on recent research and advances on the epidemiology of diabetes diagnosis, complications and prevention, the public health challenges being faced and how to prevent and deal with them.

This stream will focus on health systems and policies that affect diabetes care, and most importantly people living with diabetes. There will be a focus on both the wider funding of healthcare in general,
and on policies that impact diabetes care at a micro and macro level.

The stream gives an in-depth insight into the perspectives of people living with diabetes and highlights their role in diabetes awareness, prevention, education, support, advocacy and communication.

Basic and Translational 
Science (BTS)
Lead
Paula Macedo
Portugal
Members
Young-Bum Kim
USA
Norbert Stefan
Germany
Sung Hee Choi
South Korea
Clinical, Therapeutic
and Technology
Research (CTT)
Lead
Shashank Joshi
India
Members
David Klonoff
USA
Chantal Mathieu
Belgium
Pablo Aschner Monotoya
Columbia
Diabetes Complications
and Comorbidities (DCC)
Lead
Andrea Luk
China
Members
Kamlesh Khunti
United Kingdom
David Preiss
United Kingdom
George King
USA
Health Services and
Policy (HSP)
Lead
Niti Pall
United Kingdom
Members
Partha Kar
United Kingdom
Cajsa Lindberg
Sweden
Reem Fahd Al Bunyan
Kingdom of Saudi Arabia
Diabetes in Women (DIW)
Lead
Maria Inês Schmidt
Brazil
Members
Usha Siriam
India
Caroline Kramer
Canada
David Simmons
Australia
Education and
Integrated Care (EIC)
Lead
Zilin Sun
China
Members
Rajata Rajatanavin
Thailand
Tatjana Milenkovic
Macedonia
Edwin B Fisher
USA
Epidemiology and
Public Health (EPH)
Lead
Ayesha Motala
South Africa
Members
Elizabeth Selvin
USA
Edward Gregg
United Kingdom
Abdul Basit
Pakistan
Living with Diabetes (LWD)
Lead
Sana Ajmal
Pakistan
Members
Georgina Peters
Australia
Sebastian Hauck
Germany
Mila Clarke Buckley
USA

Programme Chair: Jonathan Shaw, Australia

Jonathan Shaw MD, FRCP (UK), FRACP, FAAHMS is Deputy Director at Melbourne’s Baker Heart and Diabetes Institute. He is also an Endocrinologist, Chair of the Diabetes Advisory Group to the Australian Institute of Health and Welfare (AIHW), Council Member of the Australian Diabetes Society, and Past-President of the International Diabetes Epidemiology Group (IDEG). His awards include the IDEG Peter Bennett Award (2011), the Australian Diabetes Society (ADS) Jeff Flack Diabetes Data Award (2015), and the ADS Kellion Diabetes Award (2018). He has authored more than 400 peer-reviewed scientific papers and 35 book chapters, and was included in the Thomson Reuters The World’s Most Influential Scientific Minds (2014), and the Clarivate Analytics list of the world’s most Highly Cited Researchers (2017 and 2018). His areas of interest include epidemiology and clinical trials in diabetes.